ABL Bio

ABL Bio ROCE

The Return on Capital Employed (ROCE) of ABL Bio (298380.KQ) as of Oct 21, 2026 is -25.70 %. In the previous year, Return on Capital Employed (ROCE) was -35.50 % — a change of -27.59% (higher).

ROCE

-25.70 %

YoY

-27.59%

Last updated:

In 2025, ABL Bio's return on capital employed (ROCE) was -25.70 %, a -27.59% increase from the -35.50 % ROCE in the previous year.

The ABL Bio ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2018
-15.31 KRW
Jan 1, 2019
-30.63 KRW
Jan 1, 2020
-65.79 KRW
Jan 1, 2021
-93.48 KRW
Jan 1, 2022
1.30 KRW
Jan 1, 2023
-3.53 KRW
Jan 1, 2024
-35.50 KRW
Jan 1, 2025
-25.70 KRW
The ABL Bio ROCE history
YEARROCEYoY
-25.70 %-27.59%
-35.50 %+904.74%
-3.53 %-370.92%
1.30 %-101.39%
-93.48 %+42.09%
-65.79 %+114.81%
-30.63 %+100.07%
-15.31 %-236.35%
11.23 %-61.37%
29.06 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

ABL Bio Stock analysis

What does ABL Bio do? ABL Bio, Inc. develops therapeutic drugs for immuno-oncology and neurodegenerative diseases, focusing on anti-angiogenesis antibodies, anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, and antibody-drug conjugates (ADCs). The company generates revenue through the development and commercialization of these advanced biopharmaceutical products, targeting pharmaceutical companies and research institutions seeking innovative treatments for cancer and neurological disorders. Its product portfolio addresses unmet medical needs in oncology and neurology, with a focus on next-generation antibody-based therapies. The company's pipeline includes multiple proprietary drug candidates designed to enhance treatment efficacy and patient outcomes in complex disease areas. ABL Bio, Inc. serves pharmaceutical companies and research institutions as its primary customers, providing them with proprietary antibody technologies and drug candidates for further development and potential commercialization. The company's products are positioned within the immuno-oncology and neurodegenerative disease segments, where demand for targeted therapies is growing. By developing novel antibody-based treatments, ABL Bio aims to capture market share in high-growth therapeutic areas, leveraging its expertise in bispecific and dual-targeting antibody platforms to address complex medical challenges. ABL Bio is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling ABL Bio's Return on Capital Employed (ROCE)

ABL Bio's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing ABL Bio's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

ABL Bio's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in ABL Bio’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about ABL Bio stock

Return on Capital Employed (ROCE) of ABL Bio is -25.70 % in 2025.

Return on Capital Employed (ROCE) of ABL Bio changed from -35.50 % to -25.70 %, representing a -27.59% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) ABL Bio since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s ABL Bio with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — ABL Bio

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — ABL Bio